MedTrace Logo

WTX212A Monotherapy and in Combination With PD -1/PD-L1 Monoclonal Antibody

NCT06106152 · Status: RECRUITING · Phase: EARLY_PHASE1 · Type: INTERVENTIONAL · Enrollment: 20

Last updated 2024-03-26

No results posted yet for this study

Summary

This trial is a single-center, open-label designed investigator-initiated clinical study (IIT) to evaluate the efficacy, safety, pharmacokinetics, and pharmacodynamics of WTX212A injection WTX212A injection combined with PD -1/PD-L1 monoclonal antibody in patients with advanced lung cancer

Conditions

Interventions

DRUG

WTX212A injection

The WTX212A infusion is given every 21 days

DRUG

PD -1/PD-L1 monoclonal antibody

The PD -1/PD-L1 monoclonal antibody is given every 21 days

Sponsors & Collaborators

  • Westlake Therapeutics

    collaborator INDUSTRY

  • Second Affiliated Hospital, School of Medicine, Zhejiang University

    lead OTHER

Principal Investigators

  • pingli wang, phD · Second Affiliated Hospital, School of Medicine, Zhejiang University

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-12-05
Primary Completion
2024-10-30
Completion
2025-12-31

Countries

  • China

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06106152 on ClinicalTrials.gov